Inhibitor Therapeutics, Inc.
INTI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $10,353 | $13,921 | $36,252 | $56,437 |
| - Cash | $5,607 | $8,840 | $11,951 | $31 |
| + Debt | $0 | $0 | $411 | $231 |
| Enterprise Value | $4,746 | $5,081 | $24,712 | $56,638 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $318 | $379 | -$0 | -$325 |
| % Margin | – | – | – | – |
| Net Income | -$3,339 | -$3,026 | $12,106 | -$299 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.019 | -0.018 | 0.03 | -0.001 |
| % Growth | -10.2% | -158.7% | 2,407.7% | – |
| Operating Cash Flow | -$3,233 | -$2,700 | $11,741 | -$220 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$3,233 | -$2,700 | $11,741 | -$220 |